Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Brussels – page 72

2 059 clinical trials in Brussels, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brussels at a glance
2 059
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

2 059 trials in Brussels

Open in trial search

Breast cancer+1

Not yet recruiting

Evaluation of Lung Function Using Xenon Gas with CT Imaging in Lung and Breast Cancer Patients Receiving Radiotherapy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Xenon (133XE)
  • Sponsor:Universitair Ziekenhuis Brussel

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Eidos Therapeutics Inc.

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Study of MIDRIX-LUNG immunotherapy combined with anti-PD-1 treatment in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Universitair Ziekenhuis Gent

Sarcopenia

Not yet recruiting

Evaluation of BIO-101 versus placebo for treating severe sarcopenia in elderly patients with reduced mobility

Investigational
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:20-HYDROXYECDYSONE
  • Sponsor:Biophytis

Transitional cell carcinoma

Not yet recruiting

Study of disitamab vedotin alone or with pembrolizumab in patients with locally advanced or metastatic urothelial cancer that expresses HER2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Bronchiectasis

Not yet recruiting

Study of Nebulized Human Normal Immunoglobulin (CSL787) for Adults with Non-cystic Fibrosis Bronchiectasis to Find Best Dose and Test Safety

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Cardiac failure+5

Not yet recruiting

Study of cardiac atrial stem cells injected into heart muscle for treating advanced heart failure in patients with prior heart attack and reduced heart function

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:CASCS
  • Sponsor:CASC8

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of OD-07656 and Vedolizumab for Patients with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Odyssey Therapeutics Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Brussels

What the registry says about research in the country

01 Oncology

In Bruxelles, several trials focus on neoplasms, especially breast cancer, colorectal cancer, lung cancer, glioblastoma, soft tissue sarcoma, and other advanced solid tumors. These studies are designed to test new treatment combinations, improve survival outcomes, and refine more personalized care for people with difficult-to-treat cancers.

  • ER-positive, HER2-negative breast cancer and related high-risk disease
  • EGFR-mutated non-small cell lung cancer and metastatic lung disease
  • Glioblastoma and other advanced brain tumors
  • Colon cancer, rectal cancer with liver metastasis, and broader advanced solid tumors

Much of this research aims to evaluate whether new therapeutic approaches can better control tumor growth and extend disease-free or overall survival.

02 Neurology and Stroke Care

Clinical trial activity in Bruxelles also includes nervous system diseases, with a strong focus on acute ischemic stroke and intracerebral haemorrhage. The main goal is to improve recovery after stroke and assess safer, more effective treatment strategies in urgent care settings.

  • Acute ischemic stroke with incomplete reperfusion
  • Stroke in patients with recent direct oral anticoagulant use
  • Intracerebral haemorrhage and prevention of later vascular events

These studies are centered on improving functional outcomes, supporting better reperfusion, and understanding how to optimize care after a stroke.

03 Respiratory and Critical Care Medicine

Research in respiratory tract diseases is active, particularly for pneumonia and severe infections requiring hospital or intensive care support. The trials are examining ways to reduce complications, improve recovery, and measure whether new add-on treatments can make standard care more effective.

  • Severe community-acquired pneumonia
  • Hospital-acquired pneumonia
  • Severe pneumonia in critically ill patients

This area includes efforts to test supportive treatments that may help improve survival and shorten the time patients spend in hospital.

04 Cardiovascular and Acute Care Research

Trials in cardiovascular diseases are studying conditions such as cardiogenic shock and other severe acute cardiac or circulatory emergencies. The research is focused on evaluating treatment effectiveness and safety in life-threatening situations where rapid decision-making is essential.

  • Cardiogenic shock linked to acute coronary syndrome
  • Cardiogenic shock of septic origin
  • Cardiogenic shock due to acute decompensated heart failure

These studies aim to provide reliable evidence on outcomes such as mortality and time to hospital discharge.

05 Dermatology and Viral Infections

A distinct group of studies addresses immune system diseases and virus diseases, with work on psoriasis, human papillomavirus, Epstein-Barr virus, and non genital warts. The research is designed to assess symptom improvement, infection clearance, and the longer-term safety of treatment options.

  • Moderate to severe plaque psoriasis
  • HPV infection and genital wart disease
  • Epstein-Barr virus infection
  • Non genital warts

These trials reflect a mix of symptom-focused and infection-focused research in common yet persistent conditions.

06 Infectious Disease and Antiviral Research

Bruxelles is also hosting studies in bacterial infections and mycoses as well as chronic viral disease, including HIV. The emphasis is on improving clinical outcomes, supporting recovery, and testing therapies that may better control infection-related complications.

  • HIV in patients with suppressed viral load
  • Hospital-acquired and severe respiratory infections
  • Viral and skin infections associated with HPV and EBV

This area combines prevention, symptom control, and treatment-response research across several infection types.

07 Breast Cancer and Personalized Treatment

Several trials are specifically focused on breast cancer, including early-stage, locally advanced, and metastatic disease. The research explores more individualized treatment strategies, including approaches guided by tumor biology and relapse risk.

  • ER-positive, HER2-negative breast carcinoma
  • Premenopausal high-risk HR-positive breast cancer
  • High-risk relapse after initial breast cancer treatment

These studies are intended to help match treatment intensity more closely to a patient’s risk profile and tumor characteristics.

08 Gastrointestinal Oncology

Research in digestive system diseases includes studies of colon cancer and rectal cancer, with special attention to older adults and patients with higher recurrence risk. The main goal is to compare treatment strategies that may improve long-term cancer control.

  • Stage III colon cancer
  • Upper rectal cancer
  • Colon and rectal cancer with liver metastasis

This work explores how postoperative treatment choices can support better relapse-free survival and overall disease management.

09 Metabolic and Autoimmune-Related Treatment Safety

Another research stream addresses longer-term treatment safety in immune system diseases, especially for chronic inflammatory conditions. In the city of Bruxelles, investigators are comparing whether newer therapies can maintain effectiveness while reducing health risks over time.

  • Moderate-to-severe plaque psoriasis
  • Cardiovascular safety in long-term treatment use
  • Comparative treatment safety in chronic inflammatory disease

These trials are aimed at supporting safer long-term management for people living with chronic conditions.

10 Not Otherwise Specified / Mixed Oncology Research

Some trials cannot be neatly placed into a single therapeutic category, but they still contribute to the broader oncology and clinical research landscape. These studies often focus on evaluating new treatment options for patients with limited standard choices.

  • Participants with advanced solid tumors
  • Metastatic or advanced cancer populations
  • Recurrent glioblastoma and other hard-to-treat disease settings

The common aim is to test whether emerging therapies can offer meaningful benefit where current options remain limited.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.